Welcome to our dedicated page for Kymera Therapeutics SEC filings (Ticker: KYMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biotechnology company focused on targeted protein degradation (TPD). Through these filings, investors can review how Kymera reports its clinical progress, collaboration agreements, financing activities and corporate governance matters.
Kymera’s current reports on Form 8-K disclose material events such as clinical data presentations for KT-621, an investigational first-in-class oral STAT6 degrader in atopic dermatitis and asthma, and updates on KT-579, an oral IRF5 degrader for immune-mediated diseases. 8-K filings also describe key collaboration developments, including the IRAK4 degrader KT-485/SAR447971 with Sanofi for immuno-inflammatory diseases and an exclusive option and license agreement with Gilead Sciences covering an oral CDK2 molecular glue degrader program for potential use in breast cancer and other solid tumors.
Filings related to public offerings and capital structure outline Kymera’s underwritten offerings of common stock and pre-funded warrants, shelf registration statements on Form S-3 and associated underwriting agreements and registration rights agreements. These documents explain how the company raises capital to advance its pipeline of preclinical and clinical degrader programs and may detail potential milestone and royalty structures under collaboration arrangements.
Users can also consult SEC filings for information on Nasdaq listing details, including the KYMR ticker on The Nasdaq Global Market, as well as shareholder meeting results, board composition and executive transitions. Stock Titan’s platform pairs these filings with AI-powered summaries that highlight key terms, material developments and financial implications, helping readers navigate complex documents such as 8-Ks, registration statements and related exhibits more efficiently.
Kymera Therapeutics (KYMR) reported insider trading activity on June 28, 2025, involving stock options granted to Baker Bros. Advisors LP and affiliated entities. Felix J. Baker, a director of Kymera, received 16,000 non-qualified stock options with the following terms:
- Exercise price: $46.47 per share
- Grant date: June 25, 2025
- Expiration date: June 24, 2035
- Vesting: Earlier of first anniversary or next annual stockholder meeting
The filing details complex beneficial ownership arrangements where Baker Bros. Advisors LP serves as investment adviser to two funds: Baker Brothers Life Sciences LP and 667 LP. Per adviser policies, Felix Baker has no direct pecuniary interest in the options, with all economic benefits flowing to the funds. Julian Baker and Felix Baker may have indirect interests through their ownership in the funds' general partners. Baker Bros. Advisors LP maintains complete voting and investment control over the securities.
Form 4 Filing Details: Jeffrey W. Albers, Director of Kymera Therapeutics (KYMR), received a stock option grant on June 25, 2025. The derivative securities transaction involved:
- Grant of 16,000 stock options to purchase common stock
- Exercise price set at $46.47 per share
- Options expire on June 24, 2035
- Vesting schedule: Full vesting upon earlier of June 25, 2026 or next annual stockholder meeting
The transaction was reported via Form 4 filing on June 28, 2025, with Bruce Jacobs signing as Attorney-in-Fact. This equity compensation grant appears to be part of the company's director compensation program, with Albers maintaining direct ownership of the derivative securities.
Kymera Therapeutics, Inc. (KYMR) filed a Form 4 on 26 June 2025 disclosing a single equity transaction for director Gorjan Hrustanovic. The filing reports the grant of a stock option covering 16,000 common shares with an exercise price of $46.47 per share.
The option was issued on 25 June 2025 and carries a ten-year term, expiring 24 June 2035. Vesting occurs in full on the earlier of (i) 25 June 2026 or (ii) the date of Kymera’s next annual shareholders’ meeting. No common shares were bought or sold in the open market; the transaction is classified as an "A" (grant) under SEC codes.
The reporting person is a member of BVF Partners L.P. and has agreed to transfer any economic benefit from the option to BVF; consequently, beneficial ownership is disclaimed beyond any pecuniary interest. Following the grant, Hrustanovic holds 16,000 derivative securities directly and reports no change in underlying common-stock ownership.
For investors, this appears to be a routine director compensation grant rather than a signal of changing sentiment or material corporate development. No immediate impact on Kymera’s capitalization, earnings outlook, or governance profile is indicated.
Form 4 Filing Details: Kymera Therapeutics (KYMR) director Pamela Esposito received a stock option grant on June 25, 2025. The derivative security consists of options to purchase 16,000 shares of common stock at an exercise price of $46.47 per share.
The stock options have the following key terms:
- Expiration date: June 24, 2035
- Vesting schedule: Full vesting upon the earlier of June 25, 2026, or the next annual stockholders' meeting
- Ownership form: Direct
This grant appears to be part of the company's director compensation program. The filing was signed by Bruce Jacobs as Attorney-in-Fact on June 26, 2025.
Form 4 Filing Details: Director John Maraganore of Kymera Therapeutics (KYMR) received a stock option grant on June 25, 2025, representing a significant insider transaction.
Key Transaction Details:
- Acquired 16,000 stock options with exercise price of $46.47 per share
- Options expire on June 24, 2035
- Vesting occurs at earlier of June 25, 2026 or next annual stockholder meeting
- Transaction reported as direct ownership
This grant appears to be part of the company's director compensation program. The options provide Maraganore with the right to purchase KYMR shares at the specified strike price, aligning his interests with shareholders through potential stock price appreciation over the next decade.
Kymera Therapeutics (KYMR) director Bruce Booth received a new stock option grant on June 25, 2025. The grant details include:
- 16,000 stock options with exercise price of $46.47 per share
- Options expire on June 24, 2035
- Full vesting occurs at earlier of June 25, 2026 or next annual stockholder meeting
Notable disclosure: Proceeds from any share sales upon exercise will be transferred to Atlas Venture Life Science Advisors, LLC. Booth disclaims ownership except for his pecuniary interest. This arrangement suggests institutional relationship between the director and Atlas Venture, indicating potential venture capital/investment advisory connection.
Kymera Therapeutics Director Victor Sandor received a stock option grant on June 25, 2025, according to a Form 4 filing. The grant consists of 16,000 stock options with an exercise price of $46.47 per share.
Key details of the stock option grant:
- The options expire on June 24, 2035
- Vesting occurs at the earlier of June 25, 2026 or the next annual stockholder meeting
- The derivative securities are held directly by the reporting person
- The transaction was reported through an attorney-in-fact on June 26, 2025
This grant appears to be part of the company's director compensation program, with a one-year cliff vesting schedule tied to continued board service.
Elena Ridloff, Director at Kymera Therapeutics (KYMR), received a stock option grant on June 25, 2025. The derivative securities transaction involved:
- Grant of 16,000 stock options to purchase common stock
- Exercise price set at $46.47 per share
- Options expire on June 24, 2035
- Vesting schedule: Full vesting upon the earlier of June 25, 2026 or the next annual stockholders' meeting
This Form 4 filing represents a standard director compensation equity grant. The options provide Ridloff with the right to purchase company shares at the specified strike price, aligning her interests with shareholders through direct equity ownership potential.
Kymera Therapeutics, Inc. (Nasdaq: KYMR) has filed a preliminary prospectus supplement (Rule 424(b)(5)) to sell up to $250 million of new securities comprised of common stock and pre-funded warrants. The exact share count and public offering price have not yet been set. Each warrant is immediately exercisable at an exercise price of $0.0001, does not expire, and is subject to ownership limitations and, in some cases, HSR clearance. No market will be made for these warrants and they will not be listed on Nasdaq or any other exchange.
The company has also granted underwriters Morgan Stanley, J.P. Morgan, Jefferies, TD Cowen and Leerink Partners a 30-day option to purchase up to an additional $37.5 million of common stock on the same terms. Net proceeds, before offering expenses, will equal the public offering price less underwriting discounts and commissions (detailed in the “Underwriting” section beginning on page S-22). Proceeds will augment the company’s balance sheet; specific use of funds is described in the “Use of Proceeds” section (S-19).
The supplement forms part of Kymera’s automatic shelf registration statement on Form S-3 (File No. 333-282912). Investors are urged to review the accompanying prospectus, the incorporated SEC filings and the “Risk Factors” section (page S-11) before making any investment decision. The offering will only be made by means of the prospectus; distribution may be restricted in certain jurisdictions.
Kymera Therapeutics, Inc. (Nasdaq: KYMR) has filed a preliminary prospectus supplement (Rule 424(b)(5)) to sell up to $250 million of new securities comprised of common stock and pre-funded warrants. The exact share count and public offering price have not yet been set. Each warrant is immediately exercisable at an exercise price of $0.0001, does not expire, and is subject to ownership limitations and, in some cases, HSR clearance. No market will be made for these warrants and they will not be listed on Nasdaq or any other exchange.
The company has also granted underwriters Morgan Stanley, J.P. Morgan, Jefferies, TD Cowen and Leerink Partners a 30-day option to purchase up to an additional $37.5 million of common stock on the same terms. Net proceeds, before offering expenses, will equal the public offering price less underwriting discounts and commissions (detailed in the “Underwriting” section beginning on page S-22). Proceeds will augment the company’s balance sheet; specific use of funds is described in the “Use of Proceeds” section (S-19).
The supplement forms part of Kymera’s automatic shelf registration statement on Form S-3 (File No. 333-282912). Investors are urged to review the accompanying prospectus, the incorporated SEC filings and the “Risk Factors” section (page S-11) before making any investment decision. The offering will only be made by means of the prospectus; distribution may be restricted in certain jurisdictions.
Kymera Therapeutics (NASDAQ:KYMR) announced a significant update to its Sanofi collaboration regarding IRAK4-targeting drug candidates. Sanofi has selected KT-485/SAR447971, an oral IRAK4 inhibitor for immuno-inflammatory diseases, to advance into clinical studies. The company received a $20 million milestone payment in Q2 2025 and is eligible for up to $975 million in additional milestones. Notably, Sanofi will not advance KT-474 and has exercised its participation election right for the IRAK4 target under the existing collaboration agreement.
Kymera Therapeutics (NASDAQ:KYMR) announced a significant update to its Sanofi collaboration regarding IRAK4-targeting drug candidates. Sanofi has selected KT-485/SAR447971, an oral IRAK4 inhibitor for immuno-inflammatory diseases, to advance into clinical studies. The company received a $20 million milestone payment in Q2 2025 and is eligible for up to $975 million in additional milestones. Notably, Sanofi will not advance KT-474 and has exercised its participation election right for the IRAK4 target under the existing collaboration agreement.